Functionally, NR4A1-driven CARs mediated potent tumor lysis, preserved a less exhausted (PD-1<sup>low</sup> and TIM-3<sup>low</sup>) and more memory-like phenotype (CD62L<sup>high</sup> and CD45RA<sup>high</sup>), and sustained robust antitumor responses in vitro and in vivo. This evidence concerns the gene SELL and neoplasm.